Jun 2026Neuropharmacology · 291
Awake rat neuroimaging maps dose- and sex-dependent effects of 5-MeO-DMT on functional brain connectivity across cortical and subcortical regions.
N. Cavallaro · P. Rai · 7 moreMay 2026CNS Drugs · 40(5)
A phase 2a open-label trial found a single intranasal dose of 5-MeO-DMT was well tolerated alongside stable SSRI use, with promising early reductions in depressive symptoms.
M. Seynaeve · F. Dunbar · 5 moreAug 2025Cell Reports · 44(8)
EEG recordings from 29 healthy adults show that high-dose inhaled 5-MeO-DMT reorganizes cortical slow-wave activity into a more stable, low-dimensional state.
G. Blackburne · R. McAlpine · 5 moreApr 2025Neuroscience of Consciousness · 2025(1)
Naturalistic EEG and phenomenological interviews reveal 5-MeO-DMT can induce a state of "deconstructed consciousness," marked by reduced alpha and beta brain activity.
C. Timmermann · J. Sanders · 16 moreJun 2026Psychedelics · 3
Examines claims of ancestral use of the Sonoran Desert toad and the ecological politics of toad-derived 5-MeO-DMT as the compound spreads globally.
Ortiz Bernal, A. M. · Raison, C. L. · et al.Jan 2025Cell Reports · 44(8)
A commentary on Blackburne et al.'s EEG findings, noting profoundly slowed brain activity under high-dose 5-MeO-DMT without the alpha-power reduction typical of other psychedelics.
Koch, C.Jan 2025Progress in Neuro-Psychopharmacology and Biological Psychiatry · 141
A review of preclinical and clinical evidence on how psilocybin and 5-MeO-DMT may reduce traumatic brain injury impairments through neuroplasticity, anti-inflammatory, and neuroprotective pathways.
Plummer, Z. · et al.Jan 2024Frontiers in Psychiatry · 15
A PRISMA systematic review of three clinical trials (78 participants) found a favorable short-term safety and tolerability profile for 5-MeO-DMT, with no serious adverse events or dropouts reported.
Kwaśny, A. · et al.Jun 2026Neuropharmacology · 291
Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging
Awake rat neuroimaging maps dose- and sex-dependent effects of 5-MeO-DMT on functional brain connectivity across cortical and subcortical regions.
N. Cavallaro · P. Rai · 7 moreMay 2026CNS Drugs · 40(5)
Intranasal 5-MeO-DMT concomitant with SSRI for treatment-resistant depression: A proof-of-concept trial
A phase 2a open-label trial found a single intranasal dose of 5-MeO-DMT was well tolerated alongside stable SSRI use, with promising early reductions in depressive symptoms.
M. Seynaeve · F. Dunbar · 5 moreAug 2025Cell Reports · 44(8)
Complex slow waves in the human brain under 5-MeO-DMT
EEG recordings from 29 healthy adults show that high-dose inhaled 5-MeO-DMT reorganizes cortical slow-wave activity into a more stable, low-dimensional state.
G. Blackburne · R. McAlpine · 5 moreApr 2025Neuroscience of Consciousness · 2025(1)
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness
Naturalistic EEG and phenomenological interviews reveal 5-MeO-DMT can induce a state of "deconstructed consciousness," marked by reduced alpha and beta brain activity.
C. Timmermann · J. Sanders · 16 moreJun 2026Psychedelics · 3
Fabricated ancestrality: The Sonoran Desert toad, psychedelic globalization, and the ecological politics of 5-MeO-DMT
Examines claims of ancestral use of the Sonoran Desert toad and the ecological politics of toad-derived 5-MeO-DMT as the compound spreads globally.
Ortiz Bernal, A. M. · Raison, C. L. · et al.Jan 2025Cell Reports · 44(8)
The void and the brain
A commentary on Blackburne et al.'s EEG findings, noting profoundly slowed brain activity under high-dose 5-MeO-DMT without the alpha-power reduction typical of other psychedelics.
Koch, C.Jan 2025Progress in Neuro-Psychopharmacology and Biological Psychiatry · 141
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
A review of preclinical and clinical evidence on how psilocybin and 5-MeO-DMT may reduce traumatic brain injury impairments through neuroplasticity, anti-inflammatory, and neuroprotective pathways.
Plummer, Z. · et al.Jan 2024Frontiers in Psychiatry · 15
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: A systematic review of clinical trials
A PRISMA systematic review of three clinical trials (78 participants) found a favorable short-term safety and tolerability profile for 5-MeO-DMT, with no serious adverse events or dropouts reported.
Kwaśny, A. · et al.